Clinical Trials Logo

Polycythemia Vera clinical trials

View clinical trials related to Polycythemia Vera.

Filter by:

NCT ID: NCT01236638 Completed - Clinical trials for Primary Myelofibrosis

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Start date: November 2010
Phase: Phase 2
Study type: Interventional

This extension protocol to the core study CCL09101 allows patients who have tolerated the drug and derived a clinical benefit, to continue to receive treatment beyond the 9 cycles of the core protocol. Long term safety and efficacy of CYT387 (momelotinib) will be evaluated.

NCT ID: NCT01200498 Completed - Clinical trials for Myeloproliferative Disorders

Study of SB939 in Subjects With Myelofibrosis

Start date: November 2010
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if SB939 can help to control myelofibrosis. The safety of this drug will also be studied.

NCT ID: NCT01199562 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Start date: December 2010
Phase:
Study type: Observational

RATIONALE: Infection prophylaxis and management may help prevent cytomegalovirus (CMV) infection caused by a stem cell transplant. PURPOSE:This clinical trial studies infection prophylaxis and management in treating cytomegalovirus infection in patients with hematologic malignancies previously treated with donor stem cell transplant.

NCT ID: NCT01193699 Completed - Polycythemia Vera Clinical Trials

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera

PEGINVERA
Start date: August 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is the identification of the maximum tolerated dose (MTD) of the investigational medicinal product. Moreover the safety and tolerability will be assessed and an exploratory analysis of efficacy and biomarker modulation will be performed.

NCT ID: NCT01134120 Completed - Clinical trials for Primary Myelofibrosis

A Study in Myeloproliferative Disorders

Start date: April 2010
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

NCT ID: NCT01120821 Completed - Polycythemia Vera Clinical Trials

Treatment of Polycythemia Vera With Gleevec

Start date: August 2002
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.

NCT ID: NCT01053494 Completed - Clinical trials for Chronic Myelomonocytic Leukemia

Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer

Start date: April 2010
Phase: N/A
Study type: Interventional

This clinical trial studies massage therapy given by caregiver in treating quality of life of young patients undergoing treatment for cancer. Massage therapy given by a caregiver may improve the quality of life of young patients undergoing treatment for cancer

NCT ID: NCT01038856 Terminated - Polycythemia Vera Clinical Trials

Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera

OSI-TAR-766
Start date: December 2009
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera (PV). Response rate will be assessed by improvement in the complete blood count, ultrasound of the spleen, and JAK2 molecular status. It is purposed in this study to explore a possible molecular targeting of the driving mechanism of PV.

NCT ID: NCT01014546 Terminated - Clinical trials for Primary Myelofibrosis

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Start date: April 2010
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of arsenic trioxide with or without ascorbic acid in treating patients with myelofibrosis. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving arsenic acid together with ascorbic acid may kill more cancer cells.

NCT ID: NCT00952289 Completed - Clinical trials for MPN (Myeloproliferative Neoplasms)

COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial

Start date: August 2009
Phase: Phase 3
Study type: Interventional

This was a randomized, double-blind study comparing the efficacy and safety of ruxolitinib (INCB018424) tablets to matching placebo tablets in patients diagnosed with Myelofibrosis (either Primary Myelofibrosis (PMF) or Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET-MF).